NCT05447676

Effects of 4-AP on Functional SCI Recovery

Name: Clinical Trial NCT05447676
Creator: Shirley Ryan AbilityLab
Keywords: Spinal Cord Injury, Dalfampridine, Phase 1, drug, clinical trial, United States of America

Effects of 4-AP on Functional Recovery After Spinal Cord Injury

Shirley Ryan AbilityLab·Phase 1·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Spinal Cord Injury
Drug/Device/Intervention: Dalfampridine
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Shirley Ryan AbilityLab
Location: Chicago, United States of America

Timeline & enrollment

Phase: Phase 1
Start date: Jun 30, 2022
End date: Jun 01, 2025
Enrollment: 44 participants

Primary outcome

Change in TMEPs,Change in MVC

Summary

The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.

ICD-10 classifications

Sequelae of injury of spinal cordOther injury of lumbar spinal cordInjury of spinal cord, level unspecifiedOther and unspecified injuries of thoracic spinal cordOther and unspecified injuries of cervical spinal cord

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05447676
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05447676 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shirley Ryan AbilityLab and is currently Recruiting. The study focuses on Spinal Cord Injury. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.